These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

396 related articles for article (PubMed ID: 22159672)

  • 1. The effect of teriparatide compared with risedronate on reduction of back pain in postmenopausal women with osteoporotic vertebral fractures.
    Hadji P; Zanchetta JR; Russo L; Recknor CP; Saag KG; McKiernan FE; Silverman SL; Alam J; Burge RT; Krege JH; Lakshmanan MC; Masica DN; Mitlak BH; Stock JL
    Osteoporos Int; 2012 Aug; 23(8):2141-50. PubMed ID: 22159672
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial.
    Kendler DL; Marin F; Zerbini CAF; Russo LA; Greenspan SL; Zikan V; Bagur A; Malouf-Sierra J; Lakatos P; Fahrleitner-Pammer A; Lespessailles E; Minisola S; Body JJ; Geusens P; Möricke R; López-Romero P
    Lancet; 2018 Jan; 391(10117):230-240. PubMed ID: 29129436
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vertebral fracture efficacy during risedronate therapy in patients using proton pump inhibitors.
    Roux C; Goldstein JL; Zhou X; Klemes A; Lindsay R
    Osteoporos Int; 2012 Jan; 23(1):277-84. PubMed ID: 21365461
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With Osteoporosis: A Randomized Clinical Trial.
    Miller PD; Hattersley G; Riis BJ; Williams GC; Lau E; Russo LA; Alexandersen P; Zerbini CA; Hu MY; Harris AG; Fitzpatrick LA; Cosman F; Christiansen C;
    JAMA; 2016 Aug; 316(7):722-33. PubMed ID: 27533157
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of risedronate administration in osteoporotic postmenopausal women affected by inflammatory bowel disease.
    Palomba S; Orio F; Manguso F; Falbo A; Russo T; Tolino A; Tauchmanovà L; Colao A; Doldo P; Mastrantonio P; Zullo F
    Osteoporos Int; 2005 Sep; 16(9):1141-9. PubMed ID: 15928801
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and treatment of postmenopausal osteoporosis.
    Stevenson M; Jones ML; De Nigris E; Brewer N; Davis S; Oakley J
    Health Technol Assess; 2005 Jun; 9(22):1-160. PubMed ID: 15929857
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group.
    Harris ST; Watts NB; Genant HK; McKeever CD; Hangartner T; Keller M; Chesnut CH; Brown J; Eriksen EF; Hoseyni MS; Axelrod DW; Miller PD
    JAMA; 1999 Oct; 282(14):1344-52. PubMed ID: 10527181
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of teriparatide compared with risedronate on FRAX
    Body JJ; Marin F; Kendler DL; Zerbini CAF; López-Romero P; Möricke R; Casado E; Fahrleitner-Pammer A; Stepan JJ; Lespessailles E; Minisola S; Geusens P
    Osteoporos Int; 2020 Oct; 31(10):1935-1942. PubMed ID: 32474650
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fracture rate and back pain during and after discontinuation of teriparatide: 36-month data from the European Forsteo Observational Study (EFOS).
    Fahrleitner-Pammer A; Langdahl BL; Marin F; Jakob F; Karras D; Barrett A; Ljunggren Ö; Walsh JB; Rajzbaum G; Barker C; Lems WF
    Osteoporos Int; 2011 Oct; 22(10):2709-19. PubMed ID: 21113576
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of teriparatide and bisphosphonate treatment to reduce pedicle screw loosening after lumbar spinal fusion surgery in postmenopausal women with osteoporosis from a bone quality perspective.
    Ohtori S; Inoue G; Orita S; Yamauchi K; Eguchi Y; Ochiai N; Kishida S; Kuniyoshi K; Aoki Y; Nakamura J; Ishikawa T; Miyagi M; Kamoda H; Suzuki M; Kubota G; Sakuma Y; Oikawa Y; Inage K; Sainoh T; Takaso M; Toyone T; Takahashi K
    Spine (Phila Pa 1976); 2013 Apr; 38(8):E487-92. PubMed ID: 23354115
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum sclerostin levels positively correlate with lumbar spinal bone mineral density in postmenopausal women--the six-month effect of risedronate and teriparatide.
    Polyzos SA; Anastasilakis AD; Bratengeier C; Woloszczuk W; Papatheodorou A; Terpos E
    Osteoporos Int; 2012 Mar; 23(3):1171-6. PubMed ID: 21305266
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fracture risk remains reduced one year after discontinuation of risedronate.
    Watts NB; Chines A; Olszynski WP; McKeever CD; McClung MR; Zhou X; Grauer A
    Osteoporos Int; 2008 Mar; 19(3):365-72. PubMed ID: 17938986
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness of denosumab on back pain-related disability and quality-of-life in patients with vertebral fragility fractures.
    Moretti A; de Sire A; Curci C; Toro G; Gimigliano F; Iolascon G
    Curr Med Res Opin; 2019 Jan; 35(1):151-155. PubMed ID: 30406685
    [No Abstract]   [Full Text] [Related]  

  • 14. Changes in bone mineral density at 3 years in postmenopausal women receiving anastrozole and risedronate in the IBIS-II bone substudy: an international, double-blind, randomised, placebo-controlled trial.
    Sestak I; Singh S; Cuzick J; Blake GM; Patel R; Gossiel F; Coleman R; Dowsett M; Forbes JF; Howell A; Eastell R
    Lancet Oncol; 2014 Dec; 15(13):1460-1468. PubMed ID: 25456365
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sustained efficacy of risedronate in men with primary and secondary osteoporosis: results of a 2-year study.
    Ringe JD; Farahmand P; Faber H; Dorst A
    Rheumatol Int; 2009 Jan; 29(3):311-5. PubMed ID: 18762944
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness of risedronate in osteoporotic postmenopausal women with inflammatory bowel disease: a prospective, parallel, open-label, two-year extension study.
    Palomba S; Manguso F; Orio F; Russo T; Oppedisano R; Sacchinelli A; Falbo A; Tolino A; Zullo F; Mastrantonio P
    Menopause; 2008; 15(4 Pt 1):730-6. PubMed ID: 18698280
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Two-year efficacy and tolerability of risedronate once a week for the treatment of women with postmenopausal osteoporosis.
    Harris ST; Watts NB; Li Z; Chines AA; Hanley DA; Brown JP
    Curr Med Res Opin; 2004 May; 20(5):757-64. PubMed ID: 15140343
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group.
    Reginster J; Minne HW; Sorensen OH; Hooper M; Roux C; Brandi ML; Lund B; Ethgen D; Pack S; Roumagnac I; Eastell R
    Osteoporos Int; 2000; 11(1):83-91. PubMed ID: 10663363
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum 25-hydroxy-vitamin D and the risk of fractures in the teriparatide versus risedronate VERO clinical trial.
    Minisola S; Marin F; Kendler DL; Geusens P; Zerbini CAF; Russo LA; Casado E; Fahrleitner-Pammer A; Stepan JJ; Lespessailles E; Moericke R; Bagur A; Lakatos P; López-Romero P; Body JJ
    Arch Osteoporos; 2019 Jan; 14(1):10. PubMed ID: 30659410
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Additive effect of elcatonin to risedronate for chronic back pain and quality of life in postmenopausal women with osteoporosis: a randomized controlled trial.
    Hongo M; Miyakoshi N; Kasukawa Y; Ishikawa Y; Shimada Y
    J Bone Miner Metab; 2015 Jul; 33(4):432-9. PubMed ID: 25123562
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.